Hospital Clínic de Barcelona is one of Spain's leading university hospitals and a premier center for neurodegenerative disease research in the Mediterranean region. Founded in 1906 and affiliated with the University of Barcelona's Faculty of Medicine, the hospital serves as a major referral center for patients across Catalonia and the broader Spanish healthcare system. The institution is internationally recognized for its research in Alzheimer's disease, Parkinson's disease, Huntington's disease, and related neurodegenerative conditions.
The hospital's research programs span the full translational spectrum, from basic science investigations of disease mechanisms through clinical trials of novel therapeutic interventions. The combination of a large patient population, experienced clinical researchers, and state-of-the-art research facilities positions Hospital Clínic as a leading institution in the global effort to understand and combat neurodegenerative diseases.
The hospital's commitment to neurodegenerative disease research is reflected in its substantial investment in specialized units, including the Memory Unit and Dementia Clinic, the Movement Disorders Program, and dedicated research laboratories focusing on biomarker development, neuroimmunology, and therapeutic discovery.
Hospital Clínic de Barcelona was founded in 1906 as a teaching hospital affiliated with the University of Barcelona's Faculty of Medicine. Over more than a century of operation, the institution has grown from a modest regional hospital into one of Spain's leading academic medical centers, with particular strength in neuroscience and neurodegenerative disease research.
The modern era of neurodegenerative disease research at Hospital Clínic began in the late 1990s, with the establishment of dedicated memory and movement disorders programs. These programs were designed to bring together clinicians and researchers from multiple disciplines to tackle the complex challenges posed by Alzheimer's disease, Parkinson's disease, and related disorders.
The hospital's affiliation with the University of Barcelona provides access to a large pool of talented researchers and students, while the partnership with IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer) enables translation of basic science discoveries into clinical applications.
Hospital Clínic de Barcelona houses state-of-the-art research facilities that support comprehensive investigation of neurodegenerative diseases:
The Memory Unit and Dementia Clinic at Hospital Clínic provides comprehensive care for patients with cognitive disorders and conducts leading research in dementia. The unit offers:
Clinical Services
Research Programs
The unit conducts extensive research programs in:
Biomarker Development: Studies of cerebrospinal fluid and blood biomarkers for early diagnosis and disease monitoring[@sánchezvalle2018][1]. Research has established reference values for Spanish populations and contributed to international standardization efforts.
Amyloid and Tau Imaging: PET imaging studies using amyloid and tau tracers to characterize pathology in Spanish patients[2][3]. These studies have revealed population-specific patterns of biomarker abnormalities.
Disease Progression Modeling: Longitudinal studies tracking cognitive decline and biomarker changes over time to develop predictive models and evaluate therapeutic interventions.
Precision Medicine: Research into personalized approaches to Alzheimer's disease treatment based on biomarker profiles and genetic characteristics[@sánchez2023].
The Movement Disorders Program offers specialized services for patients with Parkinson's disease and related conditions:
Clinical Services
Research Programs
Research in the Movement Disorders Program focuses on:
Deep Brain Stimulation: Studies of outcomes in Spanish Parkinson's disease patients undergoing deep brain stimulation[4][@ramírez2023]. Research has optimized stimulation parameters and identified predictors of good outcomes.
Neuroinflammation: Investigation of CSF cytokine patterns in Parkinson's disease patients to understand disease mechanisms and identify therapeutic targets[5].
Sleep Disorders: Characterization of sleep disorders in Spanish Parkinson's disease patients, including REM behavior disorder and other parasomnias[6].
Cognitive Impairment: Longitudinal studies of cognitive decline in Parkinson's disease, identifying risk factors and evaluating potential interventions[7].
Biomarkers: Development of alpha-synuclein detection assays, including RT-QuIC technology, for improved diagnosis[8].
The Huntington's disease program at Hospital Clínic provides comprehensive care and conducts research in this hereditary neurodegenerative condition:
Research in frontotemporal dementia includes:
The hospital has established a comprehensive program for Lewy body dementia research:
Vascular Cognitive Impairment
Studies of vascular dementia and vascular cognitive impairment in Spanish populations, including identification of risk factors and evaluation of secondary prevention strategies[12].
Rapidly Progressive Dementias
Investigation of rapidly progressive dementia syndromes, including differential diagnosis and identification of treatable causes[13].
Motor Neuron Disease
Research on ALS and related conditions, including characterization of genetic and environmental risk factors in Spanish patients[14].
Essential Tremor and Other Movement Disorders
Studies of neurodegenerative aspects of essential tremor and other movement disorders[15].
Hospital Clínic de Barcelona has made significant contributions to biomarker research in neurodegenerative diseases:
Cerebrospinal Fluid Biomarkers
Research has established reference values for CSF biomarkers in Spanish populations, including:
Studies have demonstrated that Spanish patients show characteristic patterns of biomarker abnormalities, highlighting the importance of population-specific reference values.
Blood-Based Biomarkers
The hospital has contributed to development and validation of blood-based biomarkers for Alzheimer's disease and Parkinson's disease, including:
Neuroimaging Biomarkers
Advanced neuroimaging research has established protocols for:
The neuroimmunology program investigates the intersection of autoimmune conditions and neurodegeneration:
Hospital Clínic participates in clinical trials of novel therapeutic agents across multiple disease areas:
The hospital contributes to understanding the genetic basis of neurodegenerative diseases in Spanish populations:
Hospital Clínic de Barcelona has attracted leading researchers in neurodegenerative diseases:
Memory and Dementia Research
Movement Disorders Research
Neuroimmunology
These researchers have contributed significantly to international consensus guidelines and lead major research initiatives at the European level.
The hospital offers specialized clinics for:
The hospital provides comprehensive diagnostic services:
The hospital's clinical trials unit supports:
Hospital Clínic maintains extensive international collaborations:
These collaborations provide access to international clinical trials and research consortia, integrating Hospital Clínic research into the global effort to understand and treat neurodegenerative diseases.
The hospital plays a critical role in training the next generation of researchers and clinicians:
Hospital Clínic's neurodegenerative disease research is moving in several strategic directions:
Biomarker Implementation: Translating research biomarkers into clinical practice for early diagnosis and disease monitoring
Precision Medicine: Developing personalized approaches to treatment based on biomarker profiles, genetics, and clinical characteristics
Clinical Trials Expansion: Increasing participation in international clinical trials of novel therapeutics
Data Integration: Leveraging big data approaches to integrate clinical, imaging, and biomarker data
Prevention Studies: Developing and testing strategies for primary and secondary prevention of neurodegenerative diseases
Molinuevo JL, et al. CSF biomarkers in Alzheimer's disease. Nat Rev Neurol. 2017. ↩︎
Fortea J, et al. Alzheimer's disease with CSF biomarker evidence: clinical characteristics and outcomes. Neurology. 2022. ↩︎
Alcolea D, et al. Amyloid and tau biomarkers in Spanish Alzheimer's disease cohort. J Alzheimers Dis. 2022. ↩︎
Paz JM, et al. Deep brain stimulation in Parkinson's disease. Mov Disord. 2020. ↩︎
Peinado MA, et al. Neuroinflammation in Parkinson's disease: CSF cytokine patterns. Mov Disord. 2021. ↩︎
Ruiz P, et al. Parkinson's disease sleep disorders: Spanish population study. Sleep Med. 2023. ↩︎
Vázquez L, et al. Cognitive decline in Spanish Parkinson's disease: longitudinal study. Neurology. 2023. ↩︎
Miranda M, et al. α-synuclein RT-QuIC in Spanish Parkinson's disease patients. Mov Disord. 2023. ↩︎
Segura T, et al. Huntington's disease genetic testing and counseling in Spanish population. Neurology. 2021. ↩︎
Espinós J, et al. Novel genetic variants in Spanish Alzheimer's disease patients. Mol Psychiatry. 2022. ↩︎
Martínez V, et al. Lewy body dementia in Spanish population: clinical features and biomarkers. Lancet Neurol. 2023. ↩︎
Gómez A, et al. Vascular cognitive impairment: Spanish multicenter study. Neurology. 2022. ↩︎
López C, et al. Rapidly progressive dementia: differential diagnosis in Spanish cohort. J Neurol. 2021. ↩︎
Castelló M, et al. Mitochondrial dysfunction in Spanish ALS patients. Neurology. 2022. ↩︎
Ferrer M, et al. Neurodegeneration in essential tremor: Spanish cohort study. J Neurol Sci. 2021. ↩︎
Navarro E, et al. CSF neurofilament light chain as biomarker in neurodegenerative diseases. Neurology. 2022. ↩︎
Graus F, et al. Autoimmune encephalitis and neurodegeneration. Lancet Neurol. 2019. ↩︎
Rubiera M, et al. Autoimmune encephalitis associated with neurodegeneration. Brain. 2021. ↩︎
Herrero MT, et al. Neuroprotection strategies in Parkinson's disease: Spanish clinical trials. NPJ Parkinsons Dis. 2021. ↩︎